Join us as we talk with Dr. Leif Bergsagel about his research to subdivide myeloma by genetic type and apply different therapy approaches to these unique variations of myeloma.

Learn why myeloma is so genetically complicated and the implications this has for personalized medicine in myeloma. Dr. Lohr, MD, PhD of the Dana Farber Cancer Institute and BROAD Institue recently published an article in Cancer Cell describing the complexity and what it means for myeloma patients.

Listen as we talk with Dr. Phillip McCarthy of the Roswell Park Cancer Institute about his work in immunotherapy, transplantation and myeloma care.

Join us as we talk with Dr. Damian Green about radiation, radioimmunotherapy and how progress is being made for high-risk patients in myeloma treatment today.

Join us as we talk with Dr. ParameswaranHari, MD, MRCP, MS, about transplants, his latest myeloma research and open clinical trials. Dr. Hari is the Armand Quick-William Stapp Professor of Hematology, Section Head of Hematological Malignancies and the Director of the Adult Blood and Marrow Transplant Program at the Medical College of Wisconsin.

Join us as we talk with Dr. Noopur Raje, MD of Massachusetts General Hospital about the research she performs in the Raje Lab to study how the bone marrow environment affects myeloma growth.

Join us as we talk with Dr. Jatin Shah about his many open mutliple myeloma clinical trials at MD Anderson. With a wave of new approaches just presented at ASH, Dr. Shah discusses the wide variety of clinical trial offerings for myeloma patients (from newly diagnosed to relapsed or refractory) that include the use of monoclonal antibodies and other cell signaling inhibitors that are now being tested in the mix with existing therapies.

What do your lab results mean and how can you learn more about your specific type of multiple myeloma? Dr. Michael J. Misialek, MD tells us that we have a pathologist that is ready and waiting to help you understand your disease.

Join us as we speak with Dr. Gareth Morgan from the Institute of Cancer Research as we discuss how we can get to personalized medicine in multiple myeloma.

Join us to discuss with Dr. Rodger Tiedemann of the Ontario Cancer Institute and the Princess Margaret Hospitel his latest discovery about why myeloma keeps returning even after stem cell and combination therapy.